Johns Hopkins School of Medicine

Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Retrieved on: 
Friday, April 28, 2023
Bevacizumab, Therapy, Q&A, Roche, RECIST, OS, Glomus tumor, Johns Hopkins School of Medicine, Oncology, Biomarker, Associate, PFS, Trial of the century, VEGF, Dor, Patient, Cancer, Webcast, Mortality, HCC, ORR, Safety, Pharmaceutical industry, Medical imaging, Tempest

In the IMbrave150 Phase 3 trial, confirmed ORR benefit correlated with overall survival (OS) benefit.2

Key Points: 
  • In the IMbrave150 Phase 3 trial, confirmed ORR benefit correlated with overall survival (OS) benefit.2
    The study was conducted in clinical collaboration with F. Hoffman La-Roche.
  • Tempest expects the full data set to be presented by Roche at a medical meeting at a later date.
  • The numerically higher response rate and proportion of patients on study with the addition of TPST-1120 is promising.
  • The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at https://ir.tempesttx.com/ .

Prevent Blindness Announces Recipients of the 2023 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award

Retrieved on: 
Wednesday, April 19, 2023
Ohio State University, University, Primary health care, Visual impairment, Australian College of Optometry, Nursing, Research to Prevent Blindness, Centers for Disease Control and Prevention, Public, OD, Johns Hopkins School of Medicine, Health status of Asian Americans, Health, Optometry, Johns Hopkins School of Nursing, Eye, Doctor of Philosophy, Associate, OSU, Essay, Public health, NORC, Population health, Korea Disease Control and Prevention Agency, Ophthalmology, Dentistry, Pharmaceutical industry, Management, Vision

CHICAGO, April 19, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety organization, has announced the recipient of the 2023 Jenny Pomeroy Award for Excellence in Vision and Public Health as Dean A. VanNasdale, Jr., OD, PhD, Associate Professor at The Ohio State University (OSU) College of Optometry, and Christina Ambrosino, medical student at Johns Hopkins School of Medicine, as the recipient of the fourth annual "Rising Visionary Award." Both award recipients will present at the 12th Annual Prevent Blindness Focus on Eye Health Summit, to be held as a virtual interactive event, on July 12-13, 2023.

Key Points: 
  • Both award recipients will present at the 12th Annual Prevent Blindness Focus on Eye Health Summit , to be held as a virtual interactive event, on July 12-13, 2023.
  • The Jenny Pomeroy Award for Excellence in Vision and Public Health is presented annually to an individual, team, or organization that has made significant contributions to the advancement of public health related to vision and eye health at the community, state, national, and/or international level.
  • Dr. VanNasdale was selected for this year's Jenny Pomeroy Award for Excellence in Vision and Public Health for his significant contributions to vision and public health research.
  • For more information on the Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, the Rising Visionary Award, or the Focus on Eye Health National Summit, please visit PreventBlindness.org, or contact [email protected] .

Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer

Retrieved on: 
Wednesday, April 19, 2023
Docetaxel, AACR, Therapy, MSN, Johns Hopkins School of Medicine, Survival, American Association for Cancer Research, Toxicity, PBLA, Doctor of Philosophy, VEGF, Animal, Metabolism, Patient, Standard of care, Doxorubicin, DFMO, Paclitaxel, Mouse, Ovarian cancer, Tumor microenvironment, Pharmaceutical industry, Topotecan

Treatment with gemcitabine, topotecan, and doxorubicin have been shown to significantly increase the in vitro toxicity of SBP-101 in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.

Key Points: 
  • Treatment with gemcitabine, topotecan, and doxorubicin have been shown to significantly increase the in vitro toxicity of SBP-101 in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
  • The SBP-101 and doxorubicin combination mice had the greatest survival time with a 265% increase in median survival compared to untreated animals.
  • The poster concludes that the treatment of C57Bl/6 mice containing VDID8+ ovarian cancer with SBP-101 in combination with doxorubicin significantly prolonged survival and decreased overall tumor burden.
  • Details of the presentation are as follows:
    Additional meeting information can be found on the AACR website: https://www.aacr.org/meeting/aacr-annual-meeting-2023/

UM SCHOOL OF MEDICINE STUDY FINDS CHATGPT HELPFUL FOR BREAST CANCER SCREENING ADVICE, WITH CERTAIN CAVEATS

Retrieved on: 
Monday, April 17, 2023
Learning, Database, Medical Affairs Bureau, University, Education, Vaccination, Medical imaging, COVID-19, University of Maryland, College Park, Radiology, ChatGPT, Lung cancer, Biomedical Research, Intelligence, Massachusetts General Hospital, University of Maryland Medical Center, Nuclear medicine, Assistant, Maryland School, University of Maryland School of Medicine, CDC, Patient, Risk, Korea Disease Control and Prevention Agency, Health, American Cancer Society, Hospital, Mammography, Breast cancer, USPSTF, Johns Hopkins School of Medicine, Dentistry, Vaccine, MD, Informatics, Medicine

BALTIMORE, April 17, 2023 /PRNewswire/ -- As more consumers turn to the newly available ChatGPT for health advice, researchers are eager to see whether the information provided by the artificial intelligence chatbot is reliable and accurate. A new study conducted by researchers at the University of Maryland School of Medicine (UMSOM) indicates that the answers generated provide correct information the vast majority of the time; sometimes, though, the information is inaccurate or even fictitious.

Key Points: 
  • In February 2023, UMSOM researchers created a set of 25 questions related to advice on getting screened for breast cancer.
  • They submitted each question to ChatGPT three times to see what responses were generated.
  • ChatGPT correctly answered questions about the symptoms of breast cancer, who is at risk, and questions on the cost, age, and frequency recommendations concerning mammograms.
  • Researchers from the Massachusetts General Hospital and the Johns Hopkins University School of Medicine also participated in this study.

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

Retrieved on: 
Friday, April 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Pancreatic cancer, SBRT, AACR, Arm, University, IV, Life, Gemcitabine, LAPC, Survival, American Association for Cancer Research, University of Pittsburgh School of Medicine, Radiation therapy, Johns Hopkins School of Medicine, Data analysis, Poster, Patient, Paclitaxel, Nausea, Diagnosis, Therapy, Wilfrid Sellars, Fatigue, Pharmaceutical industry, MD

This is the first interim analysis of the randomized multi-center Phase III open label TIGeR-PaC clinical trial, designed to investigate the Company’s first product candidate, RenovoGem.

Key Points: 
  • This is the first interim analysis of the randomized multi-center Phase III open label TIGeR-PaC clinical trial, designed to investigate the Company’s first product candidate, RenovoGem.
  • In this interim analysis, the control and treatment arms demonstrated divergence in median overall survival for patients.
  • The TIGeR-PaC Data Monitoring Committee (“DMC”) met and determined the interim data is promising and warrants continuation of this pivotal trial.
  • As of the analysis date, 45 patients from U.S. sites had been randomized in this trial.

Century Therapeutics Announces Leadership Changes

Retrieved on: 
Wednesday, April 12, 2023
Georgia Tech, Johns Hopkins University, National Science Board, Roche, Biochemistry, Strategic management, Research and development, Iran National Science Foundation, Patient, Cell, Chemical engineering, GSK plc, The Jacob Rader Marcus Center of the American Jewish Archives, IPSC, Merck & Co., Rensselaer Polytechnic Institute, Corporation, Growth, Urology, Vaccine, GSK, Duke University, Business, CAR, Science, Education minister, Century, Juno Therapeutics, Amicus Therapeutics, Therapy, Industrial, Sidney Kimmel, Commercialization, Case Western Reserve University, AstraZeneca, Executive Committee, Marcus Center, Johns Hopkins School of Medicine, Ewing Marion Kauffman Foundation, Management, Pharmaceutical industry, Limited, Celgene, Research, Rutgers University, Medicine

PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as the Company’s Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Company’s Board of Directors to pursue other opportunities. In addition, effective April 11, 2023, Michael C. Diem, M.D., was promoted to the role of Chief Financial Officer, and Hy Levitsky, M.D., assumed his prior role as President of Research and Development.

Key Points: 
  • “Lalo has played a key role in advancing Century, a premier cell therapy company, to where it is today.
  • Prior to Celgene, he held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing.
  • Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine.
  • He currently serves as a member of the Board of Directors of Replimune, Prokarium, and Carisma Therapeutics.

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Retrieved on: 
Tuesday, April 11, 2023
Stem cell, IOB, University, Johns Hopkins Hospital, Wilmer Ophthalmological Institute, Stargardt disease, Johns Hopkins School of Medicine, Geographic atrophy, RBP4, Vitamin A, Retina, Belite, Medical school, Moorfields Eye Hospital, Professor, Principal, University of Basel, Society, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical need, today announced it will host a virtual key opinion leader (KOL) event to discuss the RBP4 antagonist tinlarebant and its relevance in the treatment of Stargardt Disease 1.

Key Points: 
  • (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).
  • Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.
  • He completed residency at Tübingen’s University Eye Hospital prior to a fellowship at Moorfields Eye Hospital & Institute of Ophthalmology in London.
  • A replay will be available approximately two hours after the event for 90 days.

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

Retrieved on: 
Monday, April 3, 2023
Mevalonate pathway, Therapy, Johns Hopkins School of Medicine, Cancer, Ovary, PBLA, Research, Inflammation, Patient, Chemoprophylaxis, Johns Hopkins, Pharmaceutical industry

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine.

Key Points: 
  • MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine.
  • The collaboration is intended to expand the development of Panbela’s investigative agent ivospemin (SBP-101), including activity in models of ovarian and other cancer types, further evaluations into mechanism of action, and potential combination with CPP-1X and standard of care agents.
  • The research will be co-led by Robert Casero, Ph.D., professor, and Tracy Murray Stewart, Ph.D., Senior Research Scientist, both in oncology at Johns Hopkins University School of Medicine.
  • Prof. Casero and Dr. Murray Stewart are internationally recognized researchers in polyamine biology at the Johns Hopkins Kimmel Cancer Center whose research focuses on developing drugs that target critical pathways for chemotherapy and chemoprevention, including amine metabolism, epigenetic regulation, and inflammation.

Mydecine Reports Financial Results for the Year Ended December 2022

Retrieved on: 
Saturday, April 1, 2023
Psilocybin, Communication, Indian stock exchange, Food, Drug development, Smoking, University, Use, Service, Share (finance), Johns Hopkins School of Medicine, Clinical trial, FSE, Research, PCT, Sale, LOI, Macquarie University, JHU, Addiction, Johns Hopkins University, Patent, Investment, MDMA, Machine learning, Same, European, NIDA, OTC, World Intellectual Property Organization, Artificial intelligence, Imperial College London, FDA, Mental health, Leiden University Medical Center, Family, NEO, Pharmaceutical industry, Cryptocurrency, Holding company, Security (finance), Reinsurance, Q3

These business assets were spun out into a separate corporate entity as of October 1, 2021, therefore are not represented in the company’s year-to-date 2022 operating results.

Key Points: 
  • These business assets were spun out into a separate corporate entity as of October 1, 2021, therefore are not represented in the company’s year-to-date 2022 operating results.
  • On December 9, 2022, completed a private placement and issued 905,660 common shares for gross proceeds of $480,000.
  • On September 16, 2022, the Company completed a private placement and issued 1,754,386 common shares for gross proceeds of $1,000,000.
  • Financial Results for the Year Ended December, 2022
    Net Loss: The net loss attributable to common stockholders was $11.56 million, from operations, or a basic and diluted loss per share of $(1.34).

GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

Retrieved on: 
Wednesday, April 12, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Pacific Biosciences, Business development, Senior, Johns Hopkins School of Medicine, Life Technologies, Thermo Fisher Scientific, IP, RNA, Doctor of Philosophy, Towson University, Tempus, Johns Hopkins University, Physician, Medicine, Biology, Therapy, Labcorp, Affymetrix, Management

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.
  • Mr. Kelly will be responsible for spearheading the Company’s global business growth strategy, with a focus on diagnostic partnering and biopharmaceutical alliance programs and other corporate development initiatives to advance the Company’s strategic priorities.
  • A business leader in cancer research and genomic analysis technologies, Mr. Kelly has more than 15 years’ experience in global business and market development, companion diagnostics and biomarker strategies.
  • Prior to that, he held various clinical market development and commercial roles at Life Technologies, Pacific Biosciences and Affymetrix.